Zymeworks Inc.
ZYME
Positions held
Your positionsZYME isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Zymeworks Inc. is positioned in the rapidly growing biotechnology sector, which is expected to see significant advancements in drug development and personalized medicine.
- Revenue increased by 91% compared to the prior quarter, reaching $4.6 million.
- The company's recommendation is a strong buy, with a target mean price of $41.07.
- Zymeworks has faced challenges with a negative revenue growth rate of -90.6%, indicating struggles in maintaining sales.
- The operating margin remains severely negative at -918.2%, reflecting ongoing operational inefficiencies.
- The company reported a net income loss of $45.019 million in the latest quarter.
Fundamentals
| Market cap | $1.81B | Enterprise value | $1.54B | Trailing P/E | — | Forward P/E | 28.97 |
| PEG | — | Price / book | 22.45 | Beta | 1.17 | Dividend yield | 0.00% |
| Revenue growth | -90.6% | Earnings growth | — | Gross margin | -2.5% | Operating margin | -9.2% |
| Profit margin | 0.0% | ROE | -72.3% | ROA | -24.1% | Debt / equity | 0.20 |
| Current ratio | 6.32 | Free cash flow | -$65.06M | Analyst recommendation | strong_buy | Mean target | $41.21 |
| 52w high | $31.34 | 52w low | $16.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $4.6M | $2.4M | $2.5M | $27.6M | $48.7M | — |
| Op margin | -918.2% | -1958.0% | -1754.3% | -79.9% | -1.3% | — |
| Net income | -$45.0M | -$44.2M | -$41.2M | -$19.6M | $2.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$42.1M | -$47.1M | -$44.1M | -$22.1M | -$0.6M | — |
- Revenue +91% vs prior quarter ($4.6M vs $2.4M).
- Operating margin expanded to -918.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $106M | $76.3M | $76.0M | $412M | — |
| Op margin | -87.3% | -157.0% | -181.6% | 31.6% | — |
| Net income | -$81.1M | -$123M | -$119M | $124M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$92.5M | -$120M | -$138M | $130M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO Hire
2026-10-02 · Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
2026-09-28 · Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance
2026-09-23 · Zymeworks Completes Acquisition of Theravance Biopharma
2026-09-23 · Zymeworks Completes Acquisition of Theravance Biopharma
2026-09-20 · Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
2026-09-01 · JAZZ Rises on Updated OS Results From Gastric Cancer Study
2026-08-28 · Zymeworks (ZYME), What Is Behind The Renewed Attention?
2026-08-28 · Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run?
2026-08-26 · SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
2026-08-26 · JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
Price (daily)
Full chart · RSI · MACD · patterns